In this section

Clinical trials

Active clinical trials

Cancer Clinical Trials - PBMTC-ONC1401


Protocol Summary

    Protocol No
    PBMTC-ONC1401
    Principal Investigator
    Julie-An Talano
    Phase
    II
    Title
    The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
    Associated Disease(s)
    Acute Lymphoblastic Leukemia (ALL)
    Acute Myelogenous Leukemia (AML)
    Myeloma/Myelodysplastic Syndrome (MDS)
    Description (Summary)
    There are two main purposes or parts of this study. The first part is to study the biology of blood cells from transplant patients and blood cells from the donors. Patients may be on the first part of the study without being on the second part. The second part of this study is looking at donors with special cancer-fighting cells with unique proteins on their surface called Killer Immunoglobulin-like Receptors, or “KIRs”. In this part of the study we are looking to see if patients receiving transplants from half-matched (haploidentical) related donors that have certain KIR types will have better results than those patients transplanted using other KIR types.
    Participating Institutions
    Childrens Hospital of Wisconsin
    ClinicalTrials.gov
Contact us

For more information about cancer and blood disorders clinical trials, email us or call

(414) 955-4727

Get a second opinion

It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.

Why participate in clinical trials?

Michael Burke, MD

"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD